METOPROLOL—CONTROLLED RELEASE, ZERO ORDER KINETICS
Author:
Open Access
- 1 June 1989
- journal article
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 14 (3) , 159-179
Abstract
Metoprolol CR/ZOK (controlled release, zero order kinetics) is a new formulation of an extensively used β1-selective, β-adrenoceptor blocking drug, (β1,-blocker), designed to provide continuous, even, plasma concentrations in the therapeutic range. It should, therefore, provide an effective well-tolerated treatment for hypertension and angina pectoris and for use in secondary prevention following a myocardial infarct. The purpose of this review is to consider the need for such a formulation, to describe its pharmaceutical development, review its pharmacology and assess its efficacy and tolerability compared with other available agents.Keywords
This publication has 46 references indexed in Scilit:
- Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY studyJAMA, 1988
- Efficacy and tolerability of a new controlled-release formulation of metoprolol: A comparison with conventional metoprolol tablets in mild to moderate hypertensionEuropean Journal of Clinical Pharmacology, 1988
- Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial.Circulation, 1985
- Beta blockade during and after myocardial infarction: An overview of the randomized trialsProgress in Cardiovascular Diseases, 1985
- Medical treatment of ischaemic heart disease -- beta-blockersEuropean Heart Journal, 1985
- Beta-adrenoceptor blocking drugs: Adverse reactions and drug interactionsPharmacology & Therapeutics, 1983
- EFFECT ON MORTALITY OF METOPROLOL IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1981
- Effects on exercise tachycardia during forty-eight hours of a series of doses of atenolol, sotalol, and metoprololClinical Pharmacology & Therapeutics, 1981
- CORONARY HEART-DISEASE AFTER TREATMENT OF HYPERTENSIONThe Lancet, 1978
- Combined pharmacokinetic and pharmacodynamic studies in man of the adrenergic β1‐receptor antagonist metoprolol *Acta Pharmacologica et Toxicologica, 1975